New radioactive therapy targets Hard-to-Treat prostate cancer
NCT ID NCT07567521
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called TRC003 for men with a type of advanced prostate cancer that has spread and is no longer responding to hormone therapy or chemotherapy. TRC003 is a radioactive molecule designed to attach to prostate cancer cells and deliver radiation directly to kill them. The trial will enroll 90 participants to evaluate safety, dosing, and early signs of effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRC003 (a radioactive molecule that targets and kills prostate cancer cells)
What this could lead to
If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 90 participants, so it is not yet proven to be safe or effective. Radioactive treatments can cause side effects like damage to healthy tissues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences, Shanxi Hospital
RECRUITINGTaiyuan, Shanxi, 030013, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••